Our events

SOIRÉE DU 12 DÉCEMBRE 2018

Conférence & Cocktail AMONETA DIAGNOSTICS / ADEMTECH

Rencontrez le management de deux sociétés innovantes non cotées, en cours de levée de fonds.

AMONETA DIAGNOSTICS S.A.S. (AMONETA) est une société de biotechnologie créée en 2014 et spécialisée dans le développement, la qualification et la commercialisation de biomarqueurs innovants pour les maladies du système nerveux central. AMONETA propose un test pour le diagnostic de la Maladie d’Alzheimer, rapide, non-invasif et fiable, ne nécessitant que quelques gouttes de sang. Les résultats préliminaires montrent une fiabilité du test allant jusqu’à 95% chez l’homme, avec une sensibilité et une spécificité inégalées pour le diagnostic de la maladie d’Alzheimer. Les études cliniques d’AMONETA ont été financées par différents programmes Européens (~8 Mio €).
La levée de fonds en cours sur la plateforme Happy Capital permettra de compléter l’étude clinique finale et le lancement des actions pré-commerciales.

Je m'inscris à l'évènement

SOIRÉE DU 12 DÉCEMBRE 2018

Conférence & Cocktail AMONETA DIAGNOSTICS / ADEMTECH

Rencontrez le management de deux sociétés innovantes non cotées, en cours de levée de fonds.

ADEMTECH est une entreprise française dont le savoir-faire initial est la synthèse de particules magnétiques (breveté) utilisées par des sociétés internationales produisant des tests diagnostics immunologiques. La société développe et commercialise des produits d’une part dans le domaine de la médecine légale et d’autre part dans le domaine des maladies infectieuses en mycologie et parasitologie.

ADEMTECH vient de gagner un marché exclusif avec la police scientifique pour les scènes de crime avec sa gamme de produits d’extraction en biologie moléculaire pour l’identification génétique humaine. ADEMTECH prévoit d’élargir sa gamme de réactifs détectant des agents infectieux destinés aux Hôpitaux (deux sont déjà sur le marché).

La levée de fonds est en cours sur la plateforme Happy Capital.

Je m'inscris à l'événement

Evening of 25th September 2018

Evening of 25th September 2018

PEPTINOV Conference & Cocktail

Meet the management of two innovative start-ups, in the process of raising funds, one specializing in the treatment of chronic inflammatory diseases, the other in cancer treatments:

PEPTINOV is a biotechnology company specializing in the research and development of active immunotherapy for the treatment of chronic inflammatory diseases and in particular osteoarthritis.

Peptinov team:

René AZOULAI, General Director
Hervé DO, CFO and VP Business Development
Jean-François ZAGURY, Founder and Scientific Director

Access to peptinov documents on the crowdfunding website Happy Capital

Access to PEPTINOV documents

SOIRÉE DU 25 SEPTEMBRE 2018

SOIRÉE DU 25 SEPTEMBRE 2018

Conférence & Cocktail PEPTINOV / ONCAMINE

ONCAMINE is a biotechnology company that proposes an intelligent strategy to deprive cancer cells of polyamines, a nutrient essential for their development and multiplication.

J'accède aux documents ONCAMINE

Evening of 19th June 2018

Evening of 19th June 2018

ADOCIA Conference & Cocktail

Meet the management of ADOCIA.

Adocia specializes in the development of innovative formulations of proteins and peptides already approved for the treatment of diabetes and other metabolic diseases. Adocia’s innovative reformulation approach, based on the BioChaperone® technology platform, has enabled it to develop a broad and differentiated portfolio of clinical and preclinical products. Its business model is to license its innovations to pharmaceutical companies and to conclude partnerships such as the one signed in late April with the Chinese company Tonghua Dongbao. With the ambition to develop “medicines for all, everywhere”, Adocia has recently diversified therapeutic areas addressed and offers its technology platform to partners to optimize the development of their own injectable products.

Access to documents

Evening of 22nd May 2018

ELSALYS Conference & Cocktail

Rencontrez ou suivez en direct par internet le management d’ELSALYS BIOTECH à l’occasion de son introduction en bourse sur le marché Euronext Growth®, du 18 au 28 mai :
http://investir.elsalys.com

ELSALYS BIOTECH est une société d’immuno-oncologie en phase clinique ciblant les tumeurs et leur microenvironnement immunitaire avec des anticorps thérapeutiques de nouvelle génération. Pour convertir ces nouvelles cibles en candidats médicaments, la Société développe actuellement 5 programmes propriétaires dont LEUKOTAC® (inolimomab), un anticorps d’immunothérapie ayant démontré un bénéfice clinique en Phase III qui est aux portes de l’enregistrement dans une maladie orpheline « post cancer » de très mauvais pronostic : la réaction du greffon contre l’hôte, dans sa forme aigüe et cortico-résistante.

L’introduction en bourse servira à financer la mise sur le marché du LEUKOTAC®, prévue pour 2020, et le développement des autres produits du portefeuille. IM Europe, filiale de l’Institut Mérieux, et les Laboratoire THEA, partenaire d’un des programmes de recherche d’ELSALYS BIOTECH, ont confirmé leur participation à l’opération.

Un prospectus visé par l’AMF est disponible sans frais sur www.investir.elsalys.com et sur le site de l’AMF.  Tout investissement en actions comporte des risques. Les investisseurs sont invités à se reporter au chapitre Facteurs de risques du prospectus.

Access to documents

Evening of 16th May 2018

Evening of 16th May 2018

Néovacs Conference & Cocktail

Meet the management of Néovacs, a biotechnology company specializing in the research and development of therapeutic vaccines for the treatment of autoimmune diseases. The results of its Phase IIB clinical study in the treatment of lupus will be announced by the end of June 2018. What to expect?

Access to documents

Evening of 10th April 2018

Evening of 10th April 2018

Theranexus Conference & Cocktail

Meet the management of Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the design and development of drug candidates that play on the interaction between neurons and glial cells.

Built on a unique and patented technology, the Theranexus platform enables the generation of drug candidates with reduced development time and significantly increased market access opportunities. Its most advanced product is already in Phase 2, and is set to become the gold standard treatment for narcolepsy and excessive sleepiness in Parkinson’s disease

Access to documents

Evening of 29th March 2018

Evening of 29th March 2018

Innate Pharma Conference & Cocktail

Meet the management team of Innate Pharma, a biotechnology company that designs and develops innovative cancer immunotherapies. Its approach aims to restore the ability of the immune system to recognize and eliminate tumor cells using therapeutic antibodies. Its broad portfolio has the potential to address a large number of cancers in dire medical need. Thanks to its innovative approach, Innate Pharma was able to forge major alliances with leading biopharmaceutical companies.

Access to documents

Evening of 21st March 2018

Evening of 21st March 2018

Transgene Conference & Cocktail

Transgene develops innovative immunotherapies against cancers and infectious diseases. Our approach aims to stimulate the immune responses of patients to attack diseased cells on multiple fronts. Five products are in Phase 1 to 3 of clinical trials. With our Invir.IOTM platform, we are designing a new generation of multifunctional oncolytic viruses. Meet our management to discuss our achievements of 2017 and prospects of 2018/2019.

Register

Evening of 5th March 2018

Evening of 5th March 2018

Nicox Conference & Cocktail

Meet the Management of Nicox, an international ophthalmology company, with two products approved for commercialization in the United States by licensed third parties, developing innovative solutions for maintaining vision and improving eye health. The company’s strategy is to maximize the potential of its research platform through internal developments and collaborations with leading pharmaceutical companies.

Access to documents

Evening of 21st February 2018

Evening of 21st February 2018

Sensorion Conference & Cocktail

Meet the Management of Sensorion, a biotechnology company that develops first-in-class drugs for the treatment of inner ear diseases such as severe vertigo, tinnitus or hearing loss. There is still no cure for these highly disabling conditions that affect more than 140 million people worldwide and result in very high societal costs.

Access to documents

Evening of 30th January 2018

Evening of 30th January 2018

Cellnovo Conference & Cocktail

Meet the management of Cellnovo Group SA, a company that develops and distributes the world’s first all-in-one diabetes management system, including a ground-breaking insulin micro-pump. Cellnovo contributes to improving and simplifying the life of diabetic patients and participates in several major projects in the artificial pancreas.

Access to documents

Evening of 16th November 2017

Evening of 16th November 2017

Inauguration evening of Par'Immune

Par’Immune  is a biopharmaceutical company co-founded by Professor Monique Capron and Dr. Abderrahim Lachgar, dedicated to the development of an innovative drug candidate of parasitic origin, the P28GST. This candidate targeting autoimmune and inflammatory diseases is currently being evaluated in a Phase 2a clinical trial in patients with Crohn’s disease. In early 2018, the company will initiate its development plan to conduct two Phase 2b clinical trials in various inflammatory diseases.

Access to documents

EVENING OF 17th OCTOBER 2017

EVENING OF 17th OCTOBER 2017

PrimaDiag Conference & Cocktail

PrimaDiag is a French company developing and commercializing compact robotic platforms for the rapid automation of a wide variety of protocols in the field of molecular biology and genomics.

Access to documents


Diavein Conference Cocktail

Diavein is a start-up developing and marketing an electro-stimulation device of the vascular system. Diavein aims to relieve the sickle cell disease, the most common orphan genetic disease in the world (5 million people affected). It is characterized in particular by vaso-occlusive crises, due to obstructions of the blood vessels, very painful and too often fatal.

Access to documents

Evening of 3rd October 2017

Evening of 3rd October 2017

DEINOVE Conference & Cocktail

Presentation by the management of DEINOVE, a biotechnology company discovering, developing and producing compounds from the microbial world that are of interest to the health, nutrition and cosmetics industries.

It focuses on two major families of molecules: antibiotics and carotenoids (antioxidants) and collaborates in parallel with industrial groups seeking innovation.

Access to documents

Evening of 27th June 2017<br >BIOTECH AGORA<br >PRE-IPO, INVEST SECURITIES

Evening of 27th June 2017
BIOTECH AGORA
PRE-IPO, INVEST SECURITIES

NH TherAguix Conference & Cocktail

Presentation by the managemet of NH TherAguix,​​a pharmaceutical company developing innovative nanomedicine that improves the effectiveness of radiotherapy and reduces side effects without changing clinical practice. Its AGuIX® drug, in clinical phase 1, is a non-invasive, personalized solution that improves cancer imaging and treatment

Access to documents

SOIRÉE DU 27 JUIN 2017

SOIRÉE DU 27 JUIN 2017

Medsteer Conference & Cocktail

Presentation by the management of Medsteer, a company developing an innovative medical device for the anesthetists of the operating room. The EasyTIVA system, thanks to a patented algorithm based on cerebral activity, allows to regulate in real time the depth of the general anesthesia of the patient and to reduce the postoperative side effects. Patients wake up quickly and comfortably.

Access to documents

Evening of 23rd May 2017

Evening of 23rd May 2017

ERYTECH Conference & Cocktail

Presentation by the management of ERYTECH, a biopharmaceutical company in clinical stage that develops innovative therapies in rare forms of cancers and orphan diseases.

Based on its proprietary platform, ERYCAPS, which uses a new technology to encapsulate drugs (especially enzymes) in red blood cells, ERYTECH has developed a portfolio of candidate products addressing markets with strong medical needs.

Access to documents

Evening of 18th May 2017

Evening of 18th May 2017

Quantum Genomics Conference & Cocktail

Presentation by the management of Quantum Genomics, a company developing new therapies for unmet medical needs in the field of high blood pressure and heart failure.

During this evening, the managers will present the latest news of the company including the creation of the Shareholders’ Club.

Access to documents

Evening of 22nd February 2017

Evening of 22nd February 2017

LLTech Conference & Cocktail

Presentation by the management of LLTech, an innovative medical imaging company, specializing in real-time cancer diagnosis in the radiology and surgery room by CT SCAN OPTIQUE.

LLTech is already commercializing a system and is aiming for a $ 5 billion potential market with the development of a version intended for clinical routine in diagnosis (qualification of biopsies) and in cancer surgery (margins in real time).

Access to documents

Evening of 13th December 2016

Evening of 13th December 2016

Biophytis Conference & Cocktail

Presentation by the management of Biophytis, a company specializing in diseases related to the challenge of aging, especially those affecting muscular and visual functions.

It has a portfolio of first-in-class drug candidates to treat certain indications of sarcopenia and AMD, now without treatment.

Access to documents

Evening of 8th November 2016

Evening of 8th November 2016

Quantum Genomics Conference Cocktail

Meet the management of Quantum Genomics, a company developing new therapies for unmet medical needs in the field of high blood pressure and heart failure.

Access to documents

Evening of 5th July 2016

Evening of 5th July 2016

Cerenis Therapeutics Conference Cocktail

Meet Jean-Louis Dasseux, PhD, MBA, founder and CEO of Cerenis Therapeutics, inventor of innovative strategies based on HDL (the “good cholesterol”) for the treatment of cardiovascular and metabolic diseases.

Access to documents